Global Oral Biologics & Biosimilar Drugs Markets, 2016-2021, 2021-2026F, 2031F: Lymphocyte Modulators, Interleukin Inhibitors, & Tumor Necrosis Factor-Alpha Inhibitors - ResearchAndMarkets.com

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 17, 2022
Information
Tags: 
Health, Pharmaceutical, Molecule, Diabetes, Disease, Food, Alzheimer's disease, Sarcoma, Government, Crohn's disease, Cell, Roche, EMA, Allergan, Monocyte, Immune system, Cancer, Prevalence, AstraZeneca, Novo Nordisk, Therapy, Cytokine, Multiple sclerosis, Insulin, HIV/AIDS, GlaxoSmithKline, Growth, Biosimilar, United Nations, Sanofi, US Foods, Eli Lilly and Company, Vaccine, Concord Biotech, Macrophage, Novartis, Arthritis, Carcinoma, European Medicines Agency, Distribution, Protein, Lundbeck, Multiple myeloma, Conditional sentence, Asthma, Psoriasis, Peptide, Technology, Lymphocyte, Enterocolitis, Interleukin, Pharmacy, Pharmaceutical industry, Generic drug, Dietary supplement, Food and Drug Administration Safety and Innovation Act
Geotags: 
JAPAN, BRAZIL, UK, INDONESIA, USA, NORTH AMERICA, FRANCE, MIDDLE EAST, EUROPE, US, GERMANY, CHINA, RUSSIA, INDIA, AUSTRALIA
Summary
Key Points: 
  • Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.
  • The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.
  • The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.
  • The main therapy types of are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors and tumor necrosis factor-alpha inhibitors.


The "Oral Biologics & Biosimilar Drugs Global Market Report 2022: By Therapy, By Disease, By Molecule, By Distribution" report has been added to ResearchAndMarkets.com's offering.

The global oral biologics & biosimilar drugs market is expected to grow from $4.06 billion in 2021 to $4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The market is expected to reach $10.41 billion in 2026 at a CAGR of 20.7%.

Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.

This report focuses on oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the oral biologics & biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc., Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc., Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche.

The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.

The main therapy types of are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. Interleukins are a family of cytokines produced by lymphocytes, monocytes, macrophages, and a few other cells.

They play an important role in immune system regulation. The various disease treated include asthma, crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others by vaccines, proteins & peptides, monoclonal antibodies and others. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

North America was the largest region in the oral biologics & biosimilar drugs market in 2021. Middle East is expected to be the fargest growing region in the forecast period.

The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body.

According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.

Stringent regulations imposed on approval of biosimilar is anticipated to hinder the growth of oral biologics and biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars.

The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar market.

The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Key Topics Covered:

1. Executive Summary

2. Oral Biologics & Biosimilars Market Characteristics

3. Oral Biologics & Biosimilars Market Trends And Strategies

4. Impact Of COVID-19 On Oral Biologics & Biosimilars

5. Oral Biologics & Biosimilars Market Size And Growth

5.1. Global Oral Biologics & Biosimilars Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Oral Biologics & Biosimilars Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Oral Biologics & Biosimilars Market Segmentation

6.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Lymphocyte Modulators
  • Interleukin Inhibitors
  • Tumor Necrosis Factor-Alpha Inhibitors

6.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Asthma
  • Crohn'S Disease
  • Carcinoma
  • Arthritis
  • Diabetes
  • Multiple Myeloma
  • Enterocolitis
  • Multiple Sclerosis
  • Sarcoma
  • Psoriasis and Others

6.3. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Vaccines
  • Proteins & Peptides
  • Monoclonal Antibodies
  • Others

6.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Oral Biologics & Biosimilars Market Regional And Country Analysis

7.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Companies Mentioned

  • Novartis
  • Rani Therapeutics
  • Eli Lilly and Co.
  • AstraZeneca plc.
  • Novo Nordisk A/S
  • Biocon Limited
  • Oramed Pharmaceuticals
  • BiosanaPharma
  • Entera Bio Ltd.
  • Allergan plc.
  • Emisphere Technologies
  • Enteris BioPharma
  • Chiasma
  • Allena Pharmaceuticals
  • Gelgen
  • Ganlee
  • 3sbio
  • Innovent
  • Retractable Technologies, inc.
  • Changchun High Tech
  • Dong Bao
  • CP Guojian
  • GlaxoSmithKline plc.
  • Concord Biotech
  • Aurobindo Pharma Ltd.
  • H.Lundbeck A/S
  • Sanofi-Aventis
  • Roche

For more information about this report visit https://www.researchandmarkets.com/r/jgu59y

Copyright: 
Copyright Business Wire 2022